Association between cardiometabolic disease and severe COVID-19: a nationwide case-control study of patients requiring invasive mechanical ventilation

Per Svensson, Robin Hofmann, Henrike Häbel, Tomas Jernberg, Per Nordberg, Per Svensson, Robin Hofmann, Henrike Häbel, Tomas Jernberg, Per Nordberg

Abstract

Aims: The risks associated with diabetes, obesity and hypertension for severe COVID-19 may be confounded and differ by sociodemographic background. We assessed the risks associated with cardiometabolic factors for severe COVID-19 when accounting for socioeconomic factors and in subgroups by age, sex and region of birth.

Methods and results: In this nationwide case-control study, 1.086 patients admitted to intensive care with COVID-19 requiring mechanical ventilation (cases), and 10.860 population-based controls matched for age, sex and district of residency were included from mandatory national registries. ORs with 95% CIs for associations between severe COVID-19 and exposures with adjustment for confounders were estimated using logistic regression. The median age was 62 years (IQR 52-70), and 3003 (24.9%) were women. Type 2 diabetes (OR, 2.3 (95% CI 1.9 to 2.7)), hypertension (OR, 1.7 (95% CI 1.5 to 2.0)), obesity (OR, 3.1 (95% CI 2.4 to 4.0)) and chronic kidney disease (OR, 2.5 (95% CI 1.7 to 3.7)) were all associated with severe COVID-19. In the younger subgroup (below 57 years), ORs were significantly higher for all cardiometabolic risk factors. The risk associated with type 2 diabetes was higher in women (p=0.001) and in patients with a region of birth outside European Union(EU) (p=0.004).

Conclusion: Diabetes, obesity and hypertension were all independently associated with severe COVID-19 with stronger associations in the younger population. Type 2 diabetes implied a greater risk among women and in non-EU immigrants. These findings, originating from high-quality Swedish registries, may be important to direct preventive measures such as vaccination to susceptible patient groups.

Trial registration number: Clinicaltrial.gov (NCT04426084).

Keywords: COVID-19; diabetes & endocrinology; hypertension; intensive & critical care.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Associations of cardiometabolic risk factors with severe COVID-19 (adjusted ORs with 95% CIs). †Adjusted for age, sex, educational level, marital status and region of birth. ‡Adjusted for age, sex, educational level, marital status, region of birth and all diagnoses in table 3.
Figure 2
Figure 2
Associations of cardiometabolic risk factors with severe COVID-19 by tertiles of age (adjusted ORs with 95% CIs).
Figure 3
Figure 3
Associations of cardiometabolic risk factors with severe COVID-19 by sex (adjusted ORs with 95% CIs). P values denote likelihood-ratio tests between a model with and one without an interaction term between the indicator variable for the subgroup and the risk factor added to model 2.
Figure 4
Figure 4
Associations of cardiometabolic risk factors with severe COVID-19 by region of birth * (adjusted ORs with 95% CIs). *EU 15 comprises of Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, UK. The Nordic countries include Denmark, Finland, Iceland, Norway and Sweden. P values denote likelihood-ratio tests between a model with and one without an interaction term between the indicator variable for the subgroup and the risk factor added to model 2.

References

    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430–6. 10.1038/s41586-020-2521-4
    1. Barron E, Bakhai C, Kar P, et al. . Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 2020;8:813–22. 10.1016/S2213-8587(20)30272-2
    1. Stefan N, Birkenfeld AL, Schulze MB, et al. . Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol 2020;16:341–2. 10.1038/s41574-020-0364-6
    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. 10.1016/S0140-6736(20)30566-3
    1. Mancia G, Rea F, Ludergnani M, et al. . Renin–Angiotensin–Aldosterone system blockers and the risk of Covid-19. N Engl J Med Overseas Ed 2020;382:2431–40. 10.1056/NEJMoa2006923
    1. Fosbøl EL, Butt JH, Østergaard L, et al. . Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 2020;324:168. 10.1001/jama.2020.11301
    1. Petrilli CM, Jones SA, Yang J, et al. . Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966. 10.1136/bmj.m1966
    1. Sattar N, McInnes IB, McMurray JJV. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation 2020;142:4–6. 10.1161/CIRCULATIONAHA.120.047659
    1. Stefan N, Causes SN. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol 2020;8:616–27. 10.1016/S2213-8587(20)30110-8
    1. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis 2020;50:54–67. 10.1007/s11239-020-02134-3
    1. Pareek M, Bangash MN, Pareek N, et al. . Ethnicity and COVID-19: an urgent public health research priority. Lancet 2020;395:1421–2. 10.1016/S0140-6736(20)30922-3
    1. Bornstein SR, Rubino F, Khunti K, et al. . Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8:546–50. 10.1016/S2213-8587(20)30152-2
    1. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed. N Engl J Med 2020;382:1194–6. 10.1056/NEJMp2002125
    1. Holman N, Knighton P, Kar P, et al. . Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020;8:823–33. 10.1016/S2213-8587(20)30271-0
    1. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. . The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659–67. 10.1007/s10654-009-9350-y
    1. Swedish registry for Intensive Care . National quality Registry for intensive care.. Available:
    1. Ludvigsson JF, Andersson E, Ekbom A, et al. . External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450. 10.1186/1471-2458-11-450
    1. Ludvigsson JF, Svedberg P, Olén O, et al. . The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol 2019;34:423–37. 10.1007/s10654-019-00511-8
    1. Oras P, Häbel H, Skoglund PH, et al. . Elevated blood pressure in the emergency department: a risk factor for incident cardiovascular disease. Hypertension 2020;75:229–36. 10.1161/HYPERTENSIONAHA.119.14002
    1. Wang D, Hu B, Hu C, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9. 10.1001/jama.2020.1585
    1. Grasselli G, Zangrillo A, Zanella A, et al. . Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–81. 10.1001/jama.2020.5394
    1. Torpy JM, Lynm C, Glass RM. The metabolic syndrome. JAMA 2006;295:850.10.1001/jama.295.7.850
    1. Schultz WM, Kelli HM, Lisko JC, et al. . Socioeconomic status and cardiovascular outcomes. Circulation 2018;137:2166–78. 10.1161/CIRCULATIONAHA.117.029652
    1. Gao C, Cai Y, Zhang K, et al. . Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J 2020;41:2058–66. 10.1093/eurheartj/ehaa433
    1. Kreutz R, Algharably EAE-H, Azizi M, et al. . Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020;116:1688–99. 10.1093/cvr/cvaa097
    1. Tziomalos K, Athyros VG, Karagiannis A, et al. . Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010;20:140–6. 10.1016/j.numecd.2009.08.006
    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860–7. 10.1038/nature05485
    1. Drummond GR, Vinh A, Guzik TJ, et al. . Immune mechanisms of hypertension. Nat Rev Immunol 2019;19:517–32. 10.1038/s41577-019-0160-5
    1. Loperena R, Van Beusecum JP, Itani HA, et al. . Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovasc Res 2018;114:1547–63. 10.1093/cvr/cvy112
    1. Siedlinski M, Jozefczuk E, Xu X, et al. . White blood cells and blood pressure: a Mendelian randomization study. Circulation 2020;141:1307–17. 10.1161/CIRCULATIONAHA.119.045102
    1. Pons S, Fodil S, Azoulay E, et al. . The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care 2020;24:353. 10.1186/s13054-020-03062-7
    1. Price-Haywood EG, Burton J, Fort D, et al. . Hospitalization and mortality among black patients and white patients with Covid-19. New England Journal of Medicine 2020;382:2534–43. 10.1056/NEJMsa2011686
    1. Lassale C, Gaye B, Hamer M, et al. . Ethnic disparities in hospitalisation for COVID-19 in England: the role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav Immun 2020;88:44–9. 10.1016/j.bbi.2020.05.074
    1. Rhodes A, Ferdinande P, Flaatten H, et al. . The variability of critical care bed numbers in Europe. Intensive Care Med 2012;38:1647–53. 10.1007/s00134-012-2627-8

Source: PubMed

3
Subskrybuj